Biomea Fusion, Inc.
BMEA
NASDAQ·Healthcare·Biotechnology·Mkt cap $138.1M
$2.03
▲ +6.28%
P/E
-4.09
Mkt Cap
$138.1M
52-Wk Range
$0.87–$2.99
52-Week Range
$0.87 - $2.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 4.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary covalent chemistry platform for selective drug targeting
- Focused pipeline in high-value precision oncology and metabolic disease segments
- Experienced management team in biopharmaceutical development and commercialization
- First-mover advantage in menin-targeting covalent inhibitor space
Bear Case
1 risk
- Low volatility (beta -0.3).
Growth
Stable outlook
Clinical development progress and potential FDA approvals of BMF-219
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+39.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BMEA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 5, 2026
Reported EPS of -$0.12 vs -$0.22 consensus (+46.3% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+46.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: D. Boral Capital · Apr 28, 2026
vs Industry
How BMEA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related